ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
AbCellera gets EUA from US FDA for its antibody Bamlanivimab, along with Etesevimab for COVID-19
February 10, 2021Lilly plans to manufacture more than 250,000 doses of the bamlanivimab and etesevimab therapy throughout Q1 2021, and up to a million doses by mid-2021. -
Lilly’s antibodies bamlanivimab and etesevimab show promise against COVID-19
January 29, 2021Eli Lilly’s neutralising antibodies bamlanivimab and etesevimab significantly reduced COVID-19-related hospitalisations and deaths in recently diagnosed, high-risk COVID-19 patients.
Pharma Sources Insight January 2025
